Immune checkpoint inhibitors are increasingly used as anti-cancer treatments; however, their use can be associated with the development of immune-related adverse events, including acute kidney injury. This Review describes the symptoms, biochemical signs and possible underlying mechanisms of immune checkpoint inhibitor-associated acute kidney injury, and proposes an approach to its diagnosis and management.
- Ben Sprangers
- David E. Leaf
- Mark A. Perazella
